[1] Lee SE, Lim JY, Kim TW, et al. Different role of circulating myeloidderived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation[J]. J Immunother Cancer, 2019, 7(1): 35. DOI: 10.1186/s40425-018-0491-y.
[2] Kaczmarek M, Nowicka A, Kozlowska M, et al. Evaluation of the phenotype pattern of macrophages isolated from malignant and nonmalignant pleural effusions[J]. Tumour Biol, 2011, 32(6): 1123-1132. DOI: 10.1007/s13277-011-0214-1.
[3] Budna J, Kaczmarek M, KoleckaBednarczyk A, et al. Enhanced suppressive activity of regulatory T cells in the microenvironment of malignant pleural effusions[J]. J Immunol Res, 2018, 2018: 9876014. DOI: 10.1155/2018/9876014.
[4] Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation[J]. J Immunol, 2002, 168(9): 4272-4276. DOI: 10.4049/jimmunol.168.9.4272.
[5] Takeuchi Y, Nishikawa H. Roles of regulatory T cells in cancer immunity[J]. Int Immunol, 2016, 28(8): 401-409. DOI: 10.1093/intimm/dxw025.
[6] DeLong P, Carroll RG, Henry AC, et al. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma[J]. Cancer Biol Ther, 2005, 4(3): 342-346.
[7] Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade[J]. Science, 2018, 359(6382): 1350-1355. DOI: 10.1126/science.aar4060.
[8] Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1positive, advanced nonsmallcell lung cancer (KEYNOTE010): a randomised controlled trial[J]. Lancet, 2016, 387(10027): 1540-1550. DOI: 10.1016/S0140-6736(15)01281-7.
[9] Brahmer JR, RodriguezAbreu D, Robinson AG, et al. Healthrelated qualityoflife results for pembrolizumab versus chemotherapy in advanced, PD-L1positive NSCLC (KEYNOTE024): a multicentre, international, randomised, openlabel phase 3 trial[J]. Lancet Oncol, 2017, 18(12): 1600-1609. DOI: 10.1016/S1470-2045(17)306903.
[10] Borghaei H, PazAres L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-smallcell lung cancer[J]. N Engl J Med, 2015, 373(17): 1627-1639. DOI: 10.1056/NEJMoa1507643.
[11] Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of Nivolumab an antiPD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-smallcell lung cancer (CheckMate 063): a phase 2, singlearm trial[J]. Lancet Oncol, 2015, 16(3): 257-265. DOI: 10.1016/S1470-2045(15)70054-9.
[12] Tseng YH, Ho HL, Lai CR, et al. PD-L1 expression of tumor cells, macrophages, and immune cells in non-small cell lung cancer patients with malignant pleural esffusion[J]. J Thorac Oncol, 2018, 13(3): 447-453. DOI: 10.1016/j.jtho.2017.10.034. |